ArticleDermatologic therapy2022
Omalizumab as a corticosteroid-sparing agent in the treatment of bullous pemphigoid.
Article in Dermatologic therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 16 citations in OpenAlex.
- Combination of Omalizumab and Dupilumab for the Treatment of Severe Bullous Pemphigoid: a Series of 6 Cases.Acta dermato-venereologica · 2025Article
- Retrospective Evaluation of Omalizumab Treatment Efficacy in Patients with Bullous Pemphigoid.Journal of clinical medicine · 2025Article
- Challenging Clinical Therapeutic Approach to Urticarial Vasculitis: A Case Series.Journal of clinical medicine · 2025Article
- Lichen planus pemphigoides treated with a low dose of oral prednisolone and omalizumab.JAAD case reports · 2024Article
- Omalizumab and Dupilumab for the Treatment of Bullous Pemphigoid: A Systematic Review.Journal of clinical medicine · 2024Review
- Pruritus Is Associated with an Increased Risk for the Diagnosis of Autoimmune Skin Blistering Diseases: A Propensity-Matched Global Study.Biomolecules · 2023Article
- The cytokine milieu of bullous pemphigoid: Current and novel therapeutic targets.Frontiers in medicine · 2023Review
- Self-reactive IgE and anti-IgE therapy in autoimmune diseases.Frontiers in pharmacology · 2023Review
- Omalizumab as a corticosteroid-sparing agent in the treatment of bullous pemphigoid.Dermatologic therapy · 2022Article
- Navigating Bullous Pemphigoid: Consensus Recommendations for Diagnosis and Management-A Canadian Perspective.Journal of cutaneous medicine and surgeryReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bullous pemphigoid (BP) is the most common autoimmune blistering skin disease, characterized by the development of autoantibodies against hemidesmosomal components BP180 and BP230. The mainstay of therapy is topical and systemic corticosteroids (CS) and immunosuppressors. As this pathology mainly involves the elderly, subjects often have numerous comorbidities that influence the clinical management. Omalizumab is a recombinant humanized monoclonal anti-IgE antibody which has recently emerged as a promising treatment for BP in patients for whom CS are contraindicated or conventional treatments have failed to control the disease. For this study, we selected five patients who presented with corticosteroid-dependent BP with a contraindication to the use of other immunosuppressive treatments. The objectives of our study were to evaluate the effectiveness of omalizumab in controlling BP and allowing to decrease the dosage of systemic CS, assessing the effects of omalizumab on the clinical manifestations and the titers of circulating anti-BP180 and BP230 antibodies, IgE and eosinophils. A reduction in the dose of systemic CS was possible in 100% of the patients and complete resolution of the clinical picture was seen in 100% for skin lesions and in 40% for pruritus. A reduction of circulating IgE was found in 40%, anti-BP180 and BP230 IgGs were decreased in 60% and eosinophils in 80%.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.